

# Special Issue

## Sonodynamic Cancer Therapy

### Message from the Guest Editors

Sonodynamic therapy (SDT) is emerging as a new tool to fight cancer in a non-invasive fashion. SDT employs the interaction between low-intensity focused ultrasound and a non-toxic sound-sensitive chemical agent that accumulates in the tumoral area, which is called a “sonosensitizer”. In vitro studies and in vivo animal models have been conducted to deepen our understanding of this new technique to be applied against melanoma, breast cancer, gliomas, and other tumors. A transition from bench to bedside is currently ongoing, with numerous clinical trials approved and open to enrollment, tackling various forms of cancer. Despite its clinical translation mechanism of action, bioeffects, sensitizers, and ultrasound parameters need to be further understood. In fact, new sonosensitizers are under investigation, such as fluorescein and nanoparticles, while SDT is also being evaluated in combination with radiotherapy, chemotherapy, and immunotherapy in a multimodal synergistic perspective. This Special Issue welcomes both original research articles and reviews.

---

### Guest Editors

Dr. Francesco Prada

Prof. Dr. Eleanor Stride

Dr. Loredana Serpe

Dr. Kismet Hossain-Ibrahim

---

### Deadline for manuscript submissions

closed (30 November 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/152781](https://mdpi.com/si/152781)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)